The impact of enzalutamide on the prostate cancer patient experience: a summary review of health-related quality of life across pivotal clinical trials

Bertrand Tombal; Arnulf Stenzl; David Cella; Yohann Loriot; Andrew J. Armstrong; Karim Fizazi; Tomasz Beer; Cora N. Sternberg; Maha Hussain; Cristina Ivanescu; Arijit Ganguli; Krishnan Ramaswamy; Fred Saad

doi:10.3390/cancers13235872

The impact of enzalutamide on the prostate cancer patient experience: a summary review of health-related quality of life across pivotal clinical trials

Bertrand Tombal, Arnulf Stenzl, David Cella, Yohann Loriot, Andrew J. Armstrong, Karim Fizazi, Tomasz Beer, Cora N. Sternberg, Maha Hussain, Cristina Ivanescu, Arijit Ganguli^*, Krishnan Ramaswamy, Fred Saad

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

This review examines the impact of treatment with enzalutamide on health-related quality of life (HRQoL) in prostate cancer patients across the disease continuum based on pivotal clinical trials. We assessed the effect of enzalutamide on pain, symptom burden and overall HRQoL from randomized controlled trials. Patient experience was evaluated in men with metastatic hormone-sensitive prostate cancer (mHSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) (pre-chemotherapy and post-chemotherapy). Patients across the disease continuum reported a generally positive status at baseline, with relatively low levels of pain and impairment due to cancer-related symptoms and high HRQoL. For patients with earlier-state prostate cancer, pain and symptom-related burden were low at study entry and remained so, regardless of whether patients received enzalutamide or control treatment. Patients with more advanced disease reported mitigation in pain and symptom burden while receiving treatment with enzalutamide. Enzalutamide was observed to slow deterioration of overall HRQoL most for patients with nmCRPC or mCRPC (statistical significance for between-group difference in median time to deterioration: mHSPC (confirmed) p = 0.2998; nmCRPC (confirmed) p = 0.0044; mCRPC (unconfirmed) p < 0.0001). Across the prostate cancer continuum, enzalutamide is well-tolerated and delays the negative impact that disease progression has on quality of life.

Original language	English (US)
Article number	5872
Journal	Cancers
Volume	13
Issue number	23
DOIs	https://doi.org/10.3390/cancers13235872
State	Published - Dec 2021

Keywords

Anti-neoplastic agents
Cancer pain
Prostatic neoplasms
Quality of life
Treatment outcome

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers13235872

Cite this

Tombal, B., Stenzl, A., Cella, D., Loriot, Y., Armstrong, A. J., Fizazi, K., Beer, T., Sternberg, C. N., Hussain, M., Ivanescu, C., Ganguli, A., Ramaswamy, K., & Saad, F. (2021). The impact of enzalutamide on the prostate cancer patient experience: a summary review of health-related quality of life across pivotal clinical trials. Cancers, 13(23), Article 5872. https://doi.org/10.3390/cancers13235872

@article{b8c512828ac54387bb685ee52576dc16,

title = "The impact of enzalutamide on the prostate cancer patient experience: a summary review of health-related quality of life across pivotal clinical trials",

abstract = "This review examines the impact of treatment with enzalutamide on health-related quality of life (HRQoL) in prostate cancer patients across the disease continuum based on pivotal clinical trials. We assessed the effect of enzalutamide on pain, symptom burden and overall HRQoL from randomized controlled trials. Patient experience was evaluated in men with metastatic hormone-sensitive prostate cancer (mHSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) (pre-chemotherapy and post-chemotherapy). Patients across the disease continuum reported a generally positive status at baseline, with relatively low levels of pain and impairment due to cancer-related symptoms and high HRQoL. For patients with earlier-state prostate cancer, pain and symptom-related burden were low at study entry and remained so, regardless of whether patients received enzalutamide or control treatment. Patients with more advanced disease reported mitigation in pain and symptom burden while receiving treatment with enzalutamide. Enzalutamide was observed to slow deterioration of overall HRQoL most for patients with nmCRPC or mCRPC (statistical significance for between-group difference in median time to deterioration: mHSPC (confirmed) p = 0.2998; nmCRPC (confirmed) p = 0.0044; mCRPC (unconfirmed) p < 0.0001). Across the prostate cancer continuum, enzalutamide is well-tolerated and delays the negative impact that disease progression has on quality of life.",

keywords = "Anti-neoplastic agents, Cancer pain, Prostatic neoplasms, Quality of life, Treatment outcome",

author = "Bertrand Tombal and Arnulf Stenzl and David Cella and Yohann Loriot and Armstrong, {Andrew J.} and Karim Fizazi and Tomasz Beer and Sternberg, {Cora N.} and Maha Hussain and Cristina Ivanescu and Arijit Ganguli and Krishnan Ramaswamy and Fred Saad",

note = "Funding Information: Acknowledgments: Medical writing support was provided by Emily Ruzich, of IQVIA, and editorial assistance was provided by Folabomi Oladosu, Jane Beck, and Lauren Smith of Complete HealthVizion, funded by the study sponsors. Stefan Holmstrom and James Turnbull assisted in conceptualizing this study. Funding Information: Funding: This study was funded by Astellas Pharma Inc. and Pfizer Inc., the co-developers of en-zalutamide. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).",

year = "2021",

month = dec,

doi = "10.3390/cancers13235872",

language = "English (US)",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "23",

}

Tombal, B, Stenzl, A, Cella, D, Loriot, Y, Armstrong, AJ, Fizazi, K, Beer, T, Sternberg, CN, Hussain, M, Ivanescu, C, Ganguli, A, Ramaswamy, K & Saad, F 2021, 'The impact of enzalutamide on the prostate cancer patient experience: a summary review of health-related quality of life across pivotal clinical trials', Cancers, vol. 13, no. 23, 5872. https://doi.org/10.3390/cancers13235872

TY - JOUR

T1 - The impact of enzalutamide on the prostate cancer patient experience

T2 - a summary review of health-related quality of life across pivotal clinical trials

AU - Tombal, Bertrand

AU - Stenzl, Arnulf

AU - Cella, David

AU - Loriot, Yohann

AU - Armstrong, Andrew J.

AU - Fizazi, Karim

AU - Beer, Tomasz

AU - Sternberg, Cora N.

AU - Hussain, Maha

AU - Ivanescu, Cristina

AU - Ganguli, Arijit

AU - Ramaswamy, Krishnan

AU - Saad, Fred

N1 - Funding Information: Acknowledgments: Medical writing support was provided by Emily Ruzich, of IQVIA, and editorial assistance was provided by Folabomi Oladosu, Jane Beck, and Lauren Smith of Complete HealthVizion, funded by the study sponsors. Stefan Holmstrom and James Turnbull assisted in conceptualizing this study. Funding Information: Funding: This study was funded by Astellas Pharma Inc. and Pfizer Inc., the co-developers of en-zalutamide. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PY - 2021/12

Y1 - 2021/12

N2 - This review examines the impact of treatment with enzalutamide on health-related quality of life (HRQoL) in prostate cancer patients across the disease continuum based on pivotal clinical trials. We assessed the effect of enzalutamide on pain, symptom burden and overall HRQoL from randomized controlled trials. Patient experience was evaluated in men with metastatic hormone-sensitive prostate cancer (mHSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) (pre-chemotherapy and post-chemotherapy). Patients across the disease continuum reported a generally positive status at baseline, with relatively low levels of pain and impairment due to cancer-related symptoms and high HRQoL. For patients with earlier-state prostate cancer, pain and symptom-related burden were low at study entry and remained so, regardless of whether patients received enzalutamide or control treatment. Patients with more advanced disease reported mitigation in pain and symptom burden while receiving treatment with enzalutamide. Enzalutamide was observed to slow deterioration of overall HRQoL most for patients with nmCRPC or mCRPC (statistical significance for between-group difference in median time to deterioration: mHSPC (confirmed) p = 0.2998; nmCRPC (confirmed) p = 0.0044; mCRPC (unconfirmed) p < 0.0001). Across the prostate cancer continuum, enzalutamide is well-tolerated and delays the negative impact that disease progression has on quality of life.

AB - This review examines the impact of treatment with enzalutamide on health-related quality of life (HRQoL) in prostate cancer patients across the disease continuum based on pivotal clinical trials. We assessed the effect of enzalutamide on pain, symptom burden and overall HRQoL from randomized controlled trials. Patient experience was evaluated in men with metastatic hormone-sensitive prostate cancer (mHSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) (pre-chemotherapy and post-chemotherapy). Patients across the disease continuum reported a generally positive status at baseline, with relatively low levels of pain and impairment due to cancer-related symptoms and high HRQoL. For patients with earlier-state prostate cancer, pain and symptom-related burden were low at study entry and remained so, regardless of whether patients received enzalutamide or control treatment. Patients with more advanced disease reported mitigation in pain and symptom burden while receiving treatment with enzalutamide. Enzalutamide was observed to slow deterioration of overall HRQoL most for patients with nmCRPC or mCRPC (statistical significance for between-group difference in median time to deterioration: mHSPC (confirmed) p = 0.2998; nmCRPC (confirmed) p = 0.0044; mCRPC (unconfirmed) p < 0.0001). Across the prostate cancer continuum, enzalutamide is well-tolerated and delays the negative impact that disease progression has on quality of life.

KW - Anti-neoplastic agents

KW - Cancer pain

KW - Prostatic neoplasms

KW - Quality of life

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85119618630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119618630&partnerID=8YFLogxK

U2 - 10.3390/cancers13235872

DO - 10.3390/cancers13235872

M3 - Article

C2 - 34884981

AN - SCOPUS:85119618630

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 23

M1 - 5872

ER -

The impact of enzalutamide on the prostate cancer patient experience: a summary review of health-related quality of life across pivotal clinical trials

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this